Skip to main content
main-content

Latest oncology news

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1814017
SABCS 2018; San Antonio, Texas, USA; 4–8 December

11-12-2018 | Oncology | Highlight | Article

Editor's pick

Direct oral anticoagulants AVERT VTE events in patients with cancer

The results of the randomized CASSINI and AVERT trials support the prophylactic use of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients undergoing chemotherapy who are at risk for venous thromboembolism events.

Source:

ASH 2018; San Diego, California, USA; 1–4 December
N Engl J Med 2018; doi:10.1056/NEJMoa1814468

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

07-12-2018 | Oncology | News | Article

News in brief

Polycystic ovary syndrome associated with increased cancer risk

Women with polycystic ovary syndrome may have an increased likelihood for developing cancer, although the excess risk appears to be primarily restricted to those who are premenopausal, indicates a population-based study.

07-12-2018 | Leukaemia | News | Article

Ibrutinib plus obinutuzumab more effective than chemoimmunotherapy in CLL

Combining ibrutinib rather than chlorambucil with obinutuzumab significantly improves progression-free survival in previously untreated patients with chronic lymphocytic leukemia, phase III study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30788-5
ASH 2018; San Diego, California, USA; 1–4 December

06-12-2018 | Leukaemia | News | Article

Ibrutinib delays progression versus chemoimmunotherapy in older CLL patients

Treatment with ibrutinib either alone or in combination with rituximab significantly delays disease progression or death compared with bendamustine plus rituximab in older patients with untreated chronic lymphocytic leukaemia, phase III trial data show.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1812836
ASH 2018; San Diego, California, USA; 1–4 December

05-12-2018 | Lymphoma | News | Article

Editor's pick

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1804980
ASH 2018; San Diego, California, USA; 1–4 December

03-12-2018 | Oncology | News | Article

approvalsWatch

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

29-11-2018 | Colorectal cancer | News | Article

Rechallenge with cetuximab, irinotecan may benefit mCRC patients

Approximately one-fifth of patients with RAS and BRAF wild-type metastatic colorectal cancer derive clinical benefit from rechallenge with cetuximab plus irinotecan, Italian researchers report.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5080

28-11-2018 | Oncology | News | Article

Editor's pick

Multiparametric MRI does not render systematic prostate biopsy obsolete

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30569-2
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30607-7

26-11-2018 | Oncology | News | Article

Adjuvant erlotinib delays recurrence in stage IA–IIIA NSCLC

Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.

Source:

J Clin Oncol 2018; doi:10.1200/JCO. 18.00131

22-11-2018 | Oncology | Main feed | News

Boosted surgical approach can match radiotherapy for prostate cancer survival

Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4836

22-11-2018 | Oncology | Main feed | News

Immune checkpoint inhibitor cardiovascular toxicity characterised

A review of individual case safety reports in a WHO global database has helped characterise the risk of cardiovascular immune-related adverse events adverse events among patients using immune checkpoint inhibitor therapy.

Source:

Lancet Oncol 2018; http://dx.doi.org/10.1016/S1470-2045(18)30608-9

20-11-2018 | Oncology | News | Article

approvalsWatch

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

19-11-2018 | Oncology | News | Article

Editor's pick

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

Source:

BMJ 2018; 363: K4266

15-11-2018 | Oncology | News | Article

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30648-X
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30674-0

15-11-2018 | Oncology | Main feed | News

Postoperative HCC recurrence surveillance should target the liver

Clinicians monitoring patients for late recurrence after curative surgery for hepatocellular carcinoma should focus on the liver, say Chinese researchers who found few patients develop only extrahepatic disease in the first instance.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.4334

13-11-2018 | Lung cancer | Main feed | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30649-1
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30789-7

12-11-2018 | Oncology | News | Article

Editor's pick

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Source:

J Clin Oncol 2018; DOI: 10.1200/JCO.18.01148

09-11-2018 | Prostate cancer | News | Article

NCRI 2018 in brief

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

image credits